跳至主要内容
临床试验/NL-OMON42765
NL-OMON42765已完成不适用

ongitudinal analysis of head and neck cancer-specific immunity in patients treated with (salvage) surgery - Tumor-specific immunity in HNSCC treated with surgery

Antoni van Leeuwenhoek Ziekenhuis0 个研究点目标入组 60 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • a. Histologically proven HPV positive or negative HNSCC with an indication for (salvage) surgery with/without adjuvant (C)RT in a curative setting
  • b. Tumor site: oral cavity, and in case of salvage surgery: all sites
  • c. Age above 18 years
  • d. Performance score WHO 0,1 or 2 at time of study entry
  • e. Written ICF

排除标准

  • a. The use of immunosuppressive drugs at start of the treatment
  • b. Anemia < 6.0 mmol/L
  • c. In case of disease relapse or progression: Any bleeding disorder or anti-coagulation therapy, that cannot be discontinued or corrected, that significantly increases the risk of a bleeding due to the biopsy.

研究者

发起方
Antoni van Leeuwenhoek Ziekenhuis

相似试验

ongitudinal analysis of head and neck... | 临床试验